These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 8216014)

  • 1. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1998 Oct; 105(10):1945-51. PubMed ID: 9787368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Michaud JE; Friren B;
    Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Sall K
    Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S155-62. PubMed ID: 10665518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of dorzolamide and pilocarpine as adjunctive therapy in patients with open-angle glaucoma and ocular hypertension.
    Hartenbaum D; Maloney S; Vaccarelli L; Liss C; Wilson H; Gormley GJ
    Clin Ther; 1999 Sep; 21(9):1533-8. PubMed ID: 10509848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group.
    Strohmaier K; Snyder E; DuBiner H; Adamsons I
    Ophthalmology; 1998 Oct; 105(10):1936-44. PubMed ID: 9787367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group.
    Strahlman ER; Vogel R; Tipping R; Clineschmidt CM
    Ophthalmology; 1996 Aug; 103(8):1283-93. PubMed ID: 8764800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.
    Strahlman E; Tipping R; Vogel R
    Arch Ophthalmol; 1995 Aug; 113(8):1009-16. PubMed ID: 7639651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
    Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group.
    Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
    Ophthalmology; 1998 Oct; 105(10):1952-9. PubMed ID: 9787369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol.
    Stewart WC; Halper LK; Johnson-Pratt L; Polis A; Hartenbaum D
    J Ocul Pharmacol Ther; 2002 Jun; 18(3):211-20. PubMed ID: 12099542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group.
    Rusk C; Sharpe E; Laurence J; Polis A; Adamsons I
    Clin Ther; 1998; 20(3):454-66. PubMed ID: 9663361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
    Strohmaier K; Snyder E; DuBiner H; Adamsons I
    Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
    J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group.
    Hutzelmann JE; Polis AB; Michael AJ; Adamsons IA
    Acta Ophthalmol Scand; 1998 Dec; 76(6):717-22. PubMed ID: 9881560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled clinical trial of dorzolamide: a single-centre subset of a multicentre study.
    Simpson AJ; Gray TB; Ballantyne C
    Aust N Z J Ophthalmol; 1996 Feb; 24(1):39-42. PubMed ID: 8743003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.
    Strahlman E; Tipping R; Vogel R
    Am J Ophthalmol; 1996 Aug; 122(2):183-94. PubMed ID: 8694086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent].
    Kobayashi M; Naito K
    Nihon Yakurigaku Zasshi; 2000 Jun; 115(6):323-8. PubMed ID: 10948564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.